Pharmacokinetics and Dynamics of Dexmedetomidine as Adjuvant in TAP Block

Assiut University

Status and phase: Completed; Phase 3; Phase 2

Conditions: Postoperative Pain

Treatments: Drug: bupivacaine; Drug: Dexmedetomidine

Study type: Interventional

Funder types: Other

Identifiers

NCT03328299

402

Details and patient eligibility

About

TAP-block has been shown to be a safe and effective postoperative analgesia method in a variety of general. Dexmedetomidine is a selective α2 agonist with 8 times more affinity for α2 adrenergic receptors compared to clonidine and possesses all the properties of α2 agonist without respiratory depression. Dexmedetomidine has been focus of interest for its broad spectrum (sedative, analgesic and anesthetic sparing) properties, making it a useful and safe adjunct in many clinical applications.

Enrollment: 24 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 24 ASA I-II
• patients (age 18-60 years
• weight 50-89 kg

Exclusion criteria

• a known allergy to the study drugs
• significant cardiac
• respiratory, renal or hepatic diseases
• bleeding diathesis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

24 participants in 2 patient groups, including a placebo group

Dexmedetomidine group

Active Comparator group

Description:

patients were given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine + dexmedetomidine 1 μg•kg-1 diluted in 20 ml saline

Treatment:

Drug: Dexmedetomidine

bupivacaine group

Placebo Comparator group

Description:

patients will given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine

Treatment:

Drug: bupivacaine